
Clinton F Stewart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3136111/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Population pharmacokinetics of crenolanib in children and young adults with brain tumors. Cancer Chemotherapy and Pharmacology, 2022, 89, 459-468.	2.3	0
2	EPCT-01. Pediatric Brain Tumor Consortium (PBTC)-055: A phase I study of trametinib and hydroxychloroquine (HCQ) for BRAF-fusion or Neurofibromatosis type-1 (NF1)-associated pediatric gliomas. Neuro-Oncology, 2022, 24, i35-i35.	1.2	0
3	LGG-06. Selumetinib in pediatric patients with non-neurofibromatosis type 1-associated, non-optic pathway (OPG) and non-pilocytic recurrent/progressive low-grade glioma harboring BRAFV600E mutation or BRAF-KIAA1549 fusion: a multicenter prospective Pediatric Brain Tumor Consortium (PBTC) Phase 2 trial. Neuro-Oncology. 2022. 24. i88-i88.	1.2	3
4	Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. Science Translational Medicine, 2021, 13, .	12.4	26
5	A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTCâ€042). Pediatric Blood and Cancer, 2021, 68, e28879.	1.5	24
6	A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro-Oncology, 2021, 23, 1777-1788.	1.2	68
7	A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clinical Cancer Research, 2021, 27, 2442-2451.	7.0	13
8	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Journal of Clinical Oncology, 2021, 39, 822-835.	1.6	106
9	Modelâ€based evaluation of imageâ€guided fractionated wholeâ€brain radiation therapy in pediatric diffuse intrinsic pontine glioma xenografts. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 599-610.	2.5	3
10	LC-MS/MS method for quantitation of gemcitabine and its metabolite 2′,2′-difluoro-2′-deoxyuridine in mouse plasma and brain tissue: Application to a preclinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2021, 198, 114025.	2.8	0
11	Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study. Clinical and Translational Science, 2021, 14, 2152-2160.	3.1	2
12	Abstract 1357: Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas. , 2021, , .		1
13	Abstract 1358: Model-based evaluation of pegfilgrastim effects on chemotherapy-induced neutropenia in infants with CNS tumors. , 2021, , .		Ο
14	Lorlatinib in a Child with <i>ALK</i> -Fusion–Positive High-Grade Glioma. New England Journal of Medicine, 2021, 385, 761-763.	27.0	27
15	Development and validation of an LC-MS/MS method to quantify the bromodomain and extra-terminal (BET) inhibitor JQ1 in mouse plasma and brain microdialysate: Application to cerebral microdialysis study. Journal of Pharmaceutical and Biomedical Analysis, 2021, 204, 114274.	2.8	3
16	Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas. Cancer Chemotherapy and Pharmacology, 2021, 88, 1009-1020.	2.3	6
17	Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib. Clinical Pharmacokinetics, 2021, 60, 283-303.	3.5	16
18	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell, 2021, 39, 1519-1530.e4.	16.8	64

#	Article	IF	CITATIONS
19	Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG. Neuro-Oncology Advances, 2021, 3, vdab179.	0.7	5
20	CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model. European Journal of Pharmaceutical Sciences, 2020, 142, 105106.	4.0	11
21	An LC/ESI–MS/MS method to quantify the PI3K inhibitor GDCâ€0084 in human plasma and cerebrospinal fluid: Validation and clinical application. Biomedical Chromatography, 2020, 34, e4697.	1.7	1
22	Pharmacokinetic basis for dosing highâ€dose methotrexate in infants and young children with malignant brain tumours. British Journal of Clinical Pharmacology, 2020, 86, 362-371.	2.4	17
23	A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. European Journal of Cancer, 2020, 137, 204-213.	2.8	39
24	The RACE to Develop New Targeted Therapies for Children With CNS Tumors. Clinical Pharmacology and Therapeutics, 2020, 108, 434-436.	4.7	3
25	LC-MS/MS method for quantitation of the CK2 inhibitor silmitasertib (CX-4945) in human plasma, CSF, and brain tissue, and application to a clinical pharmacokinetic study in children with brain tumors. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1152, 122254.	2.3	10
26	Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing. Clinical Cancer Research, 2020, 26, 1563-1573.	7.0	14
27	A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors. Cancer, 2020, 126, 1749-1757.	4.1	10
28	Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenibÂand low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours. European Journal of Cancer, 2020, 132, 35-42.	2.8	13
29	Phase II study of alisertib as a single agent in recurrent or progressive atypical teratoid rhabdoid tumors Journal of Clinical Oncology, 2020, 38, 10542-10542.	1.6	4
30	Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. Cancer Chemotherapy and Pharmacology, 2019, 84, 829-838.	2.3	6
31	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncology, The, 2019, 20, 1011-1022.	10.7	315
32	CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors. Cancer Chemotherapy and Pharmacology, 2019, 84, 447-452.	2.3	19
33	CNS Penetration of Cyclophosphamide and Metabolites in Mice Bearing Group 3 Medulloblastoma and Non-Tumor Bearing Mice. Journal of Pharmacy and Pharmaceutical Sciences, 2019, 22, 612-629.	2.1	8
34	Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations. Cancer Letters, 2019, 442, 262-270.	7.2	23
35	Factors influencing the intracellular exposure of gemcitabine triphosphate in children with CNS tumors Journal of Clinical Oncology, 2019, 37, e13547-e13547.	1.6	0
36	Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive highâ€grade and diffuse intrinsic pontine glioma. Pediatric Blood and Cancer, 2018, 65, e27035.	1.5	36

#	Article	IF	CITATIONS
37	Development and validation of a sensitive LC MS/MS method for the measurement of the checkpoint kinase 1 inhibitor prexasertib and its application in a cerebral microdialysis study. Journal of Pharmaceutical and Biomedical Analysis, 2018, 156, 97-103.	2.8	5
38	Establishing a Preclinical Multidisciplinary Board for Brain Tumors. Clinical Cancer Research, 2018, 24, 1654-1666.	7.0	12
39	Determining success rates of the current pharmacokinetically guided dosing approach of topotecan in pediatric oncology patients. Pediatric Blood and Cancer, 2018, 66, e27578.	1.5	3
40	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncology, The, 2018, 19, 768-784.	10.7	151
41	Palmarâ€plantar erythrodysesthesia syndrome following treatment with highâ€dose methotrexate or highâ€dose cytarabine. Cancer, 2017, 123, 3602-3608.	4.1	11
42	Development and validation of LC–MS/MS methods for the measurement of ribociclib, a CDK4/6 inhibitor, in mouse plasma and Ringer's solution and its application to a cerebral microdialysis study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1057, 110-117.	2.3	20
43	Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients. Pediatric Nephrology, 2017, 32, 1575-1584.	1.7	18
44	A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro-Oncology, 2017, 19, 1135-1144.	1.2	236
45	A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Cancer Chemotherapy and Pharmacology, 2017, 80, 1013-1026.	2.3	20
46	Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies. Clinical Pharmacology and Therapeutics, 2017, 102, 752-753.	4.7	5
47	Bridging Adult Experience to Pediatrics in Oncology Drug Development. Journal of Clinical Pharmacology, 2017, 57, S129-S135.	2.0	5
48	A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. International Journal of Cancer, 2017, 141, 1469-1477.	5.1	42
49	Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. Journal of Clinical Oncology, 2017, 35, 72-77.	1.6	42
50	Abstract A33: An individualized predictive 3D model of tumor response to topotecan for a patient-derived orthotopic xenograft model of pediatric neuroblastoma. , 2017, , .		0
51	Feasibility of Pegylated Interferon in Children and Young Adults With Resected Highâ€Risk Melanoma. Pediatric Blood and Cancer, 2016, 63, 1207-1213.	1.5	20
52	Determination of methotrexate, 7-hydroxymethotrexate, and 2,4-diamino- <i>N</i> ¹⁰ -methylpteroic acid by LC–MS/MS in plasma and cerebrospinal fluid and application in a pharmacokinetic analysis of high-dose methotrexate. Journal of Liquid Chromatography and Related Technologies, 2016, 39, 745-751.	1.0	21
53	Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study. Drug Metabolism and Disposition, 2016, 44, 591-594.	3.3	3
54	Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell, 2016, 29, 508-522.	16.8	226

#	Article	IF	CITATIONS
55	Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. Drug Metabolism and Disposition, 2016, 44, 1116-1122.	3.3	15
56	Phase II evaluation of sunitinib in the treatment of recurrent or refractory highâ€grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. Cancer Medicine, 2016, 5, 1416-1424.	2.8	53
57	A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. Journal of Neuro-Oncology, 2016, 129, 443-451.	2.9	69
58	Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors. Journal of Neuro-Oncology, 2016, 126, 225-234.	2.9	11
59	Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma. JAMA Oncology, 2016, 2, 201.	7.1	41
60	Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. Clinical Pharmacokinetics, 2016, 55, 297-311.	3.5	44
61	Phase I expansion cohort to evaluate bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumors Journal of Clinical Oncology, 2016, 34, 10519-10519.	1.6	0
62	Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients. Pediatric Blood and Cancer, 2015, 62, 1518-1522.	1.5	29
63	Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Child's Nervous System, 2015, 31, 1283-1289.	1.1	41
64	Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro-Oncology, 2015, 17, 1620-1627.	1.2	24
65	Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature Genetics, 2015, 47, 263-266.	21.4	109
66	Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. Journal of Neuro-Oncology, 2015, 121, 217-224.	2.9	20
67	Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study. Cancer Chemotherapy and Pharmacology, 2015, 75, 897-906.	2.3	8
68	A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Child's Nervous System, 2015, 31, 1433-1445.	1.1	14
69	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. Journal of Clinical Oncology, 2015, 33, 2646-2654.	1.6	368
70	Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemotherapy and Pharmacology, 2015, 75, 495-503.	2.3	16
71	Response to: comment on "Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections― Cancer Chemotherapy and Pharmacology, 2015, 75, 877-878.	2.3	1
72	An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). Journal of Neuro-Oncology, 2015, 123, 85-91.	2.9	52

#	Article	IF	CITATIONS
73	ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy. Cancer Research, 2015, 75, 3879-3889.	0.9	30
74	Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemotherapy and Pharmacology, 2015, 75, 27-35.	2.3	25
75	Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells. Cancer Research, 2015, 75, 181-193.	0.9	76
76	Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML. Blood, 2015, 126, 3695-3695.	1.4	6
77	Developmental pharmacokinetics of topotecan (TPT), a renally excreted drug, in infants and young children with brain tumors Journal of Clinical Oncology, 2015, 33, 10055-10055.	1.6	0
78	Abstract 4526: Age dependent disposition of cyclophosphamide (CTX) and metabolites in infants ≤ year old with brain tumors. , 2015, , .		0
79	Abstract 4519: Development of a whole body physiologically-based pharmacokinetic (PBPK) model with individualized tumor compartment for topotecan (TPT) in mice bearing neuroblastoma (NB). , 2015, , .		0
80	Observational Evaluations of Mice during Cerebral Microdialysis for Pediatric Brain Tumor Research. Journal of the American Association for Laboratory Animal Science, 2015, 54, 304-10.	1.2	2
81	Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization–tandem mass spectrometry (LC-ESI–MS/MS). Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 960, 151-157.	2.3	21
82	Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma. Cancer Cell, 2014, 25, 516-529.	16.8	128
83	Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing. Clinical Cancer Research, 2014, 20, 2783-2792.	7.0	37
84	Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 73, 561-568.	2.3	13
85	Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro-Oncology, 2014, 16, 848-855.	1.2	62
86	First-in-pediatrics phase I study of crenolanib besylate (CP-868,596-26) administered during and after radiation therapy (RT) in newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent high-grade glioma (HGG) Journal of Clinical Oncology, 2014, 32, 10064-10064.	1.6	5
87	A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report Journal of Clinical Oncology, 2014, 32, 10065-10065.	1.6	10
88	Clinical Pharmacology in Pediatrics. Cancer Drug Discovery and Development, 2014, , 625-659.	0.4	1
89	Similar exposure and pharmacokinetics of bevacizumab in pediatric and adult cancer patients: Analysis of individual data of 152 pediatric patients Journal of Clinical Oncology, 2014, 32, 10062-10062.	1.6	0
90	A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Journal of Neuro-Oncology, 2013, 114, 173-179.	2.9	55

#	Article	IF	CITATIONS
91	The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin-Induced Ototoxicity in Children With Cancer. Clinical Pharmacology and Therapeutics, 2013, 94, 252-259.	4.7	80
92	Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study. Clinical Cancer Research, 2013, 19, 6305-6312.	7.0	180
93	Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors. Clinical Cancer Research, 2013, 19, 236-246.	7.0	64
94	Determination of crenolanib in human serum and cerebrospinal fluid by liquid chromatography–electrospray ionization-tandem mass spectrometry (LC–ESI-MS/MS). Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 929, 1-5.	2.3	5
95	Effect on Prediction When Modeling Covariates in Bayesian Nonparametric Models. Journal of Statistical Theory and Practice, 2013, 7, 204-218.	0.5	5
96	A phaseâ€1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: A pediatric brain tumor consortium study. Pediatric Blood and Cancer, 2013, 60, 627-632.	1.5	20
97	Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2013, 19, 3050-3058.	7.0	82
98	Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children's Oncology Group. Neuro-Oncology, 2013, 15, 1438-1444.	1.2	36
99	Crenolanib is active against models of drug-resistant FLT3-ITDâ^'positive acute myeloid leukemia. Blood, 2013, 122, 3607-3615.	1.4	159
100	Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer. Anticancer Research, 2013, 33, 3823-9.	1.1	12
101	Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. Clinical Cancer Research, 2012, 18, 2679-2686.	7.0	69
102	Intra-Ophthalmic Artery Chemotherapy Triggers Vascular Toxicity through Endothelial Cell Inflammation and Leukostasis. , 2012, 53, 2439.		56
103	Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors. Pediatric Blood and Cancer, 2012, 58, 372-379.	1.5	30
104	Resumption of highâ€dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer, 2012, 118, 4321-4330.	4.1	62
105	Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer, 2012, 118, 5663-5670.	4.1	40
106	A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Investigational New Drugs, 2012, 30, 1660-1670.	2.6	27
107	Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts. PLoS ONE, 2012, 7, e33894.	2.5	49
108	Comprehensive preclinical testing for neuroblastoma using orthotopic xenografts of a patient tumor Journal of Clinical Oncology, 2012, 30, e13584-e13584.	1.6	1

#	Article	IF	CITATIONS
109	Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2011, 29, 4351-4357.	1.6	124
110	Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration. Drug Metabolism and Disposition, 2011, 39, 15-21.	3.3	53
111	Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2561-2566.	2.3	25
112	Real-Time Ophthalmoscopic Findings of Superselective Intraophthalmic Artery Chemotherapy in a Nonhuman Primate Model. JAMA Ophthalmology, 2011, 129, 1458.	2.4	46
113	MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochemical Pharmacology, 2011, 82, 24-34.	4.4	19
114	An Integrated InÂVitro and InÂVivo High-Throughput Screen Identifies Treatment Leads for Ependymoma. Cancer Cell, 2011, 20, 384-399.	16.8	105
115	Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid. Cancer Chemotherapy and Pharmacology, 2011, 68, 721-731.	2.3	14
116	Magnetic Resonance Imaging–Guided Microdialysis Cannula Implantation in a Spontaneous High-Grade Glioma Murine Model. Journal of Pharmaceutical Sciences, 2011, 100, 4210-4214.	3.3	12
117	Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer, 2011, 117, 421-434.	4.1	46
118	Targeting the p53 Pathway in Retinoblastoma with Subconjunctival Nutlin-3a. Cancer Research, 2011, 71, 4205-4213.	0.9	89
119	Phase I Trial of MK-0752 in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology, 2011, 29, 3529-3534.	1.6	151
120	Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation. Clinical Cancer Research, 2011, 17, 89-99.	7.0	97
121	A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: A report from the Pediatric Brain Tumor Consortium. Neuro-Oncology, 2011, 13, 290-297.	1.2	110
122	Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2011, 29, 208-213.	1.6	127
123	Phase I Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors: Pediatric Brain Tumor Consortium Study PBTC-018. Journal of Clinical Oncology, 2011, 29, 324-329.	1.6	83
124	Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Cancer, 2010, 116, 98-105.	4.1	24
125	Determination of dopamine, serotonin, and their metabolites in pediatric cerebrospinal fluid by isocratic high performance liquid chromatography coupled with electrochemical detection. Biomedical Chromatography, 2010, 24, 626-631.	1.7	84
126	A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemotherapy and Pharmacology, 2010, 65, 353-361.	2.3	172

#	Article	IF	CITATIONS
127	Determination of the γ-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC–ESI-MS/MS). Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2348-2352.	2.3	7
128	Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC–ESI-MS/MS). Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 915-920.	2.8	8
129	A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study. Pediatric Blood and Cancer, 2010, 55, 440-445.	1.5	45
130	Modeling Covariates with Nonparametric Bayesian Methods. SSRN Electronic Journal, 2010, , .	0.4	0
131	Tyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas. Cancer Research, 2010, 70, 4499-4508.	0.9	68
132	Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology, 2010, 28, 4221-4227.	1.6	71
133	Stability of Cyclophosphamide in Extemporaneous Oral Suspensions. Annals of Pharmacotherapy, 2010, 44, 295-301.	1.9	13
134	Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with Medulloblastoma. Clinical Cancer Research, 2010, 16, 1049-1057.	7.0	11
135	Phase I Study of Vandetanib During and After Radiotherapy in Children With Diffuse Intrinsic Pontine Glioma. Journal of Clinical Oncology, 2010, 28, 4762-4768.	1.6	108
136	Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report. Journal of Clinical Oncology, 2010, 28, 3623-3629.	1.6	174
137	Clinical Pharmacology in the Adolescent Oncology Patient. Journal of Clinical Oncology, 2010, 28, 4790-4799.	1.6	93
138	Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib. European Journal of Cancer, 2010, 46, 2045-2051.	2.8	15
139	A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. European Journal of Cancer, 2010, 46, 3287-3293.	2.8	59
140	P-Glycoprotein, but not Multidrug Resistance Protein 4, Plays a Role in the Systemic Clearance of Irinotecan and SN-38 in Mice. Drug Metabolism Letters, 2010, 4, 195-201.	0.8	29
141	Abstract 2758: Population pharmacokinetics of cyclophosphamide in infants and young children. , 2010, , .		0
142	Compartment-Specific Roles of ATP-Binding Cassette Transporters Define Differential Topotecan Distribution in Brain Parenchyma and Cerebrospinal Fluid. Cancer Research, 2009, 69, 5885-5892.	0.9	52
143	Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2009, 27, 4599-4604.	1.6	53
144	Phase I Trial of Oral Irinotecan and Temozolomide for Children With Relapsed High-Risk Neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium Study. Journal of Clinical Oncology, 2009, 27, 1290-1296.	1.6	69

#	Article	IF	CITATIONS
145	Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma. Clinical Cancer Research, 2009, 15, 701-707.	7.0	64
146	Pharmacokinetics of Erlotinib for the Treatment of Highâ€Grade Glioma in a Pediatric Patient with Cystic Fibrosis: Case Report and Review of the Literature. Pharmacotherapy, 2009, 29, 858-866.	2.6	13
147	Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors. Cancer, 2009, 115, 655-664.	4.1	11
148	Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors. Cancer, 2009, 115, 1765-1775.	4.1	15
149	Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood. Biomedical Chromatography, 2009, 23, 707-713.	1.7	15
150	Simultaneous determination of cyclophosphamide and carboxyethylphosphoramide mustard in human plasma using online extraction and electrospray tandem mass spectrometry (HTLC–ESI-MS/MS). Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 1709-1715.	2.3	16
151	Treating children with acute lymphoblastic leukemia and Down syndrome: Pharmacokinetics provides insight into vincristine therapy. Pediatric Blood and Cancer, 2009, 52, 1-2.	1.5	3
152	Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2009, 53, 594-598.	1.5	28
153	Expression of the Multi-Drug Resistance Proteins and the Pregnane X Receptor in Treated and Untreated Retinoblastoma. Current Eye Research, 2009, 34, 386-394.	1.5	12
154	In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines. Cancer Chemotherapy and Pharmacology, 2008, 62, 51-58.	2.3	11
155	Reducing irinotecan-associated diarrhea in children. Pediatric Blood and Cancer, 2008, 50, 201-207.	1.5	39
156	A modified surgical procedure for microdialysis probe implantation in the lateral ventricle of a FVB mouse. Journal of Pharmaceutical Sciences, 2008, 97, 5013-5023.	3.3	5
157	Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer, 2008, 112, 1983-1991.	4.1	22
158	Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. American Journal of Physiology - Cell Physiology, 2008, 295, C440-C450.	4.6	127
159	Phase I Trial of VNP40101M (Cloretazine) in Children with Recurrent Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clinical Cancer Research, 2008, 14, 1124-1130.	7.0	20
160	Amifostine Protects Against Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma. Journal of Clinical Oncology, 2008, 26, 3749-3755.	1.6	119
161	Phase I Clinical Trial of Cilengitide in Children With Refractory Brain Tumors: Pediatric Brain Tumor Consortium Study PBTC-012. Journal of Clinical Oncology, 2008, 26, 919-924.	1.6	143
162	Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma. Clinical Cancer Research, 2008, 14, 318-325.	7.0	55

#	Article	IF	CITATIONS
163	Stability of Sunitinib in Oral Suspension. Annals of Pharmacotherapy, 2008, 42, 962-966.	1.9	12
164	IFN-β sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating <i>O</i> 6-methylguanine DNA methyltransferase expression. Molecular Cancer Therapeutics, 2008, 7, 3852-3858.	4.1	22
165	Phase I Clinical Trial of Oxaliplatin in Children and Adolescents With Refractory Solid Tumors. Journal of Clinical Oncology, 2007, 25, 2274-2280.	1.6	28
166	Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2007, 25, 4806-4812.	1.6	149
167	Topotecan Is Active Against Wilms' Tumor: Results of a Multi-Institutional Phase II Study. Journal of Clinical Oncology, 2007, 25, 3130-3136.	1.6	60
168	Continuous Delivery of IFN-β Promotes Sustained Maturation of Intratumoral Vasculature. Molecular Cancer Research, 2007, 5, 531-542.	3.4	32
169	Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients. Clinical Cancer Research, 2007, 13, 6703-6711.	7.0	21
170	Phase I Trial of Single-Dose Temozolomide and Continuous Administration of <i>O</i> 6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report. Clinical Cancer Research, 2007, 13, 6712-6718.	7.0	62
171	Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420. Clinical Cancer Research, 2007, 13, 1511-1515.	7.0	89
172	Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy. Clinical Cancer Research, 2007, 13, 3942-3950.	7.0	401
173	Substrate Overlap between Mrp4 and Abcg2/Bcrp Affects Purine Analogue Drug Cytotoxicity and Tissue Distribution. Cancer Research, 2007, 67, 6965-6972.	0.9	89
174	Interferon β–mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model. Journal of Pediatric Surgery, 2007, 42, 160-165.	1.6	17
175	UGT1A1 Promoter Genotype Correlates With SN-38 Pharmacokinetics, but Not Severe Toxicity in Patients Receiving Low-Dose Irinotecan. Journal of Clinical Oncology, 2007, 25, 2594-2600.	1.6	84
176	Determination of Cloretazineâ,,¢ (VNP40101M) and its active metabolite (VNP4090CE) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC–ESI-MS/MS). Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 853, 97-104.	2.3	4
177	Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2007, 60, 661-670.	2.3	16
178	Evaluation of Gefitinib for Treatment of Refractory Solid Tumors and Central Nervous System Malignancies in Pediatric Patients. Cancer Investigation, 2006, 24, 310-317.	1.3	39
179	Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncology, The, 2006, 7, 813-820.	10.7	811
180	Pharmacokinetic Considerations in the Treatment of CNS Tumours. Clinical Pharmacokinetics, 2006, 45, 871-903.	3.5	65

#	Article	IF	CITATIONS
181	Immunohistochemical Detection of Multidrug-Resistant Protein Expression in Retinoblastoma Treated by Primary Enucleation. , 2006, 47, 1269.		40
182	Cyclophosphamide disposition in an anephric child. Pediatric Blood and Cancer, 2006, 46, 99-104.	1.5	12
183	Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer. Pediatric Blood and Cancer, 2006, 47, 572-579.	1.5	9
184	Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC–ESI-MS/MS). Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 831, 169-175.	2.3	49
185	Temozolomide after Radiotherapy for Newly Diagnosed High-grade Glioma and Unfavorable Low-grade Glioma in Children. Journal of Neuro-Oncology, 2006, 76, 313-319.	2.9	76
186	A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. Journal of Neuro-Oncology, 2006, 77, 193-198.	2.9	23
187	Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2006, 57, 15-24.	2.3	22
188	Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children. Cancer Chemotherapy and Pharmacology, 2006, 57, 475-482.	2.3	11
189	Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors. Cancer, 2006, 107, 2291-2297.	4.1	51
190	Topotecan Central Nervous System Penetration Is Altered by a Tyrosine Kinase Inhibitor. Cancer Research, 2006, 66, 11305-11313.	0.9	79
191	Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma1. Neuro-Oncology, 2006, 8, 89-95.	1.2	11
192	Evaluation of the Antitumor Efficacy, Pharmacokinetics, and Pharmacodynamics of the Histone Deacetylase Inhibitor Depsipeptide in Childhood Cancer Models In vivo. Clinical Cancer Research, 2006, 12, 223-234.	7.0	89
193	Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2006, 24, 563-570.	1.6	70
194	Gefitinib Modulates the Function of Multiple ATP-Binding Cassette Transporters <i>In vivo</i> . Cancer Research, 2006, 66, 4802-4807.	0.9	154
195	Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report. Journal of Clinical Oncology, 2006, 24, 3678-3685.	1.6	81
196	Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood, 2005, 105, 2571-2576.	1.4	124
197	Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children. Cancer, 2005, 103, 133-139.	4.1	101
198	Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. Cancer Chemotherapy and Pharmacology, 2005, 55, 433-438.	2.3	8

#	Article	IF	CITATIONS
199	Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemotherapy and Pharmacology, 2005, 56, 629-636.	2.3	60
200	Topotecan Combination Chemotherapy in Two New Rodent Models of Retinoblastoma. Clinical Cancer Research, 2005, 11, 7569-7578.	7.0	117
201	Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children's Oncology Group Study. Journal of Clinical Oncology, 2005, 23, 6172-6180.	1.6	98
202	Improved Response in High-Risk Neuroblastoma With Protracted Topotecan Administration Using a Pharmacokinetically Guided Dosing Approach. Journal of Clinical Oncology, 2005, 23, 4039-4047.	1.6	77
203	A Phase I Trial Defining the Maximum Tolerated Systemic Exposure of Topotecan in Combination with Carboplatin and Etoposide in Extensive Stage Small Cell Lung Cancer. Cancer Investigation, 2005, 23, 511-519.	1.3	2
204	Results of a Phase II Upfront Window of Pharmacokinetically Guided Topotecan in High-Risk Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor. Journal of Clinical Oncology, 2004, 22, 3357-3365.	1.6	74
205	Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors. Clinical Cancer Research, 2004, 10, 840-848.	7.0	127
206	Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy. Molecular and Cellular Biology, 2004, 24, 7612-7621.	2.3	403
207	Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice. Cancer Research, 2004, 64, 7491-7499.	0.9	193
208	Phase I and Pharmacokinetic Study of Topotecan Administered Orally Once Daily for 5 Days for 2 Consecutive Weeks to Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2004, 22, 829-837.	1.6	29
209	Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro. Cancer Research, 2004, 64, 2333-2337.	0.9	312
210	Determination of Depsipeptide (FR901228) in Human Plasma by Liquid Chromatography–Tandem Mass Spectrometry. Journal of Liquid Chromatography and Related Technologies, 2004, 27, 3265-3278.	1.0	3
211	Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/â^'p53â^'/â^' mice. Cancer Cell, 2004, 6, 229-240.	16.8	491
212	Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. Cancer Chemotherapy and Pharmacology, 2004, 53, 253-260.	2.3	17
213	Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF. Journal of Pharmaceutical Sciences, 2004, 93, 2284-2295.	3.3	32
214	Determination of Gefitinib in Plasma by Liquid Chromatography with a C12 Column and Electrospray Tandem Mass Spectrometry Detection. Journal of Liquid Chromatography and Related Technologies, 2004, 27, 2743-2758.	1.0	15
215	Topotecan Disposition in an Anephric Child. Journal of Pediatric Hematology/Oncology, 2004, 26, 596-600.	0.6	11
216	Effect of Fractionated Ifosfamide on the Pharmacokinetics of Irinotecan in Pediatric Patients With Osteosarcoma. Journal of Pediatric Hematology/Oncology, 2004, 26, 764-767.	0.6	16

#	Article	IF	CITATIONS
217	Pharmacokinetics of Anticancer Drugs in Children. , 2004, , 395-419.		1
218	Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemotherapy and Pharmacology, 2003, 52, 435-441.	2.3	48
219	Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer, 2003, 97, 2374-2380.	4.1	14
220	Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 784, 225-232.	2.3	24
221	A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. Mathematical Biosciences, 2003, 186, 29-41.	1.9	37
222	Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237. Neuro-Oncology, 2003, 5, 261-267.	1.2	28
223	Topoisomerase I interactive agents. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 69-101.	0.5	13
224	A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clinical Cancer Research, 2003, 9, 633-40.	7.0	53
225	The importance of pharmacokinetic limited sampling models for childhood cancer drug development. Clinical Cancer Research, 2003, 9, 5068-77.	7.0	21
226	The Importance of Tumor Glucuronidase in the Activation of Irinotecan in a Mouse Xenograft Model. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 649-655.	2.5	15
227	Interim Comparison of a Continuous Infusion Versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2002, 20, 4217-4224.	1.6	65
228	Protracted Intermittent Schedule of Topotecan in Children With Refractory Acute Leukemia: A Pediatric Oncology Group Study. Journal of Clinical Oncology, 2002, 20, 1617-1624.	1.6	34
229	Phase I Study of Combination Topotecan and Carboplatin in Pediatric Solid Tumors. Journal of Clinical Oncology, 2002, 20, 88-95.	1.6	37
230	An Overview of the Pharmacokinetic Disposition of Darbepoetin alfa. Pharmacotherapy, 2002, 22, 133S-140S.	2.6	13
231	New liquid chromatographic assay with electrochemical detection for the measurement of amifostine and WR1065. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 772, 257-265.	2.3	11
232	Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clinical Cancer Research, 2002, 8, 2202-9.	7.0	44
233	Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. Clinical Cancer Research, 2002, 8, 2488-98.	7.0	28
234	Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. Cancer Chemotherapy and Pharmacology, 2001, 47, 89-93.	2.3	16

#	Article	IF	CITATIONS
235	Clinical use of topoisomerase I inhibitors in anticancer treatment. Medical and Pediatric Oncology, 2000, 35, 385-402.	1.0	48
236	Direct Translation of a Protracted Irinotecan Schedule From a Xenograft Model to a Phase I Trial in Children. Journal of Clinical Oncology, 1999, 17, 1815-1815.	1.6	217
237	Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study. Journal of Neuro-Oncology, 1999, 43, 43-47.	2.9	42
238	Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemotherapy and Pharmacology, 1999, 43, 269-276.	2.3	42
239	Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemotherapy and Pharmacology, 1999, 43, 454-460.	2.3	62
240	Phase I study of DMP 840 in pediatric patients with refractory solid tumors. Investigational New Drugs, 1998, 16, 45-49.	2.6	16
241	Animal models for studying the action of topoisomerase I targeted drugs. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1400, 301-319.	2.4	41
242	Relationship Between Topotecan Systemic Exposure and Tumor Response in Human Neuroblastoma Xenografts. Journal of the National Cancer Institute, 1998, 90, 505-511.	6.3	117
243	Efficacy of oral irinotecan against neuroblastoma xenografts. Anti-Cancer Drugs, 1997, 8, 313-322.	1.4	42
244	Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemotherapy and Pharmacology, 1997, 40, 259-265.	2.3	42
245	Schedule-dependent Efficacy of Camptothecins in Models of Human Cancer. Annals of the New York Academy of Sciences, 1996, 803, 188-201.	3.8	42
246	Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five-Day Course in Children with Refractory Solid Tumors. Journal of Pediatric Hematology/Oncology, 1996, 18, 352-361.	0.6	108
247	Topoisomerase I interactive drugs in children with cancer. Investigational New Drugs, 1996, 14, 37-47.	2.6	42
248	Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. Cytometry, 1995, 19, 134-145.	1.8	37
249	Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemotherapy and Pharmacology, 1995, 37, 195-202.	2.3	127
250	Successful treatment of metastatic choriocarcinoma after DMP 840. Urologic Oncology: Seminars and Original Investigations, 1995, 1, 166-167.	1.6	2
251	Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemotherapy and Pharmacology, 1994, 34, S76-S83.	2.3	29
252	Disposition of total and unbound etoposide following high-dose therapy. Cancer Chemotherapy and Pharmacology, 1993, 32, 273-278.	2.3	31

#	Article	IF	CITATIONS
253	Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 1992, 31, 161-166.	2.3	27
254	Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemotherapy and Pharmacology, 1992, 31, 229-239.	2.3	208
255	Factors Affecting In Vitro Protein Binding of Etoposide in Humans. Journal of Pharmaceutical Sciences, 1992, 81, 259-264.	3.3	16
256	Interspecies differences in in vitro etoposide plasma protein binding. Biochemical Pharmacology, 1991, 42, 2246-2249.	4.4	13
257	Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clinical Pharmacology and Therapeutics, 1991, 50, 385-393.	4.7	88
258	High-Performance Liquid Chromatographic Determination of Etoposide in Plasma. Journal of Liquid Chromatography and Related Technologies, 1991, 14, 1275-1283.	1.0	9
259	Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis and Rheumatism, 1991, 34, 1514-1520.	6.7	71
260	Inhaled Albuterol and Oral Prednisone Therapy in Hospitalized Adult Asthmatics. Chest, 1990, 98, 1317-1321.	0.8	70
261	Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clinical Pharmacology and Therapeutics, 1990, 47, 540-546.	4.7	56
262	Clinical pharmacodynamics of continuous-infusion etoposide. Cancer Chemotherapy and Pharmacology, 1990, 25, 361-366.	2.3	55
263	Stability-indicating high-performance liquid chromatographic method for the simultaneous determination of cisplatin and 5-fluorouracil in 0.9% sodium chloride for injection. Biomedical Applications, 1990, 528, 517-525.	1.7	5
264	Biotechnology products: New opportunities and responsibilities for the pharmacist. American Journal of Health-System Pharmacy, 1989, 46, S4-S8.	1.0	1
265	The pharmacist as educator in biotechnology: Introduction. American Journal of Health-System Pharmacy, 1989, 46, S3-S4.	1.0	0
266	Stability of cisplatin and etoposide in intravenous admixtures. American Journal of Health-System Pharmacy, 1989, 46, 1400-1404.	1.0	4
267	Altered protein binding of etoposide in patients with cancer. Clinical Pharmacology and Therapeutics, 1989, 45, 49-55.	4.7	81
268	Evaluation of Aminoglycoside Disposition in Patients Previously Treated with Cisplatin. Therapeutic Drug Monitoring, 1989, 11, 631-636.	2.0	23
269	Clinical pharmacology of anticancer drugs in children: differences and similarities between children and adults. , 1987, , 29-71.		0
270	Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clinical Pharmacology and Therapeutics, 1983, 33, 301-307.	4.7	78

#	Article	IF	CITATIONS
271	Pharmacokinetics of Anticancer Drugs in Children. Drug Metabolism Reviews, 1983, 14, 847-886.	3.6	22
272	Disposition of Intermediate-Dose Methotrexate in Children with Acute Lymphocytic Leukemia. Drug Intelligence & Clinical Pharmacy, 1982, 16, 839-842.	0.4	24
273	A Randomized-Blinded Evaluation of Analytical Error Associated with the Enzyme Immunoassay (EMIT®) of Gentamicin. Therapeutic Drug Monitoring, 1982, 4, 409-412.	2.0	0
274	Ecthyma Gangrenosum. Drug Intelligence & Clinical Pharmacy, 1979, 13, 692-696.	0.4	0